Pfizer’s Tax Practices Scrutinized: Senate Report Reveals Global Profit Shifting Tactics

Pharmaceutical giant Pfizer has come under scrutiny for its tax practices, as outlined in a recent report by the Senate Finance Committee led by panel Democrats. The report reveals that Pfizer reported no taxable profits in its largest market—the United States—by channeling its income through jurisdictions with more favorable tax laws, such as Puerto Rico, Singapore, and Ireland. This strategy has ostensibly allowed the company to significantly reduce its tax liability in the U.S., drawing attention from lawmakers and regulators concerned about corporate tax avoidance tactics. The committee’s findings highlight the ongoing debate over multinational corporations’ tax practices and the regulatory frameworks governing them.